2,378 Matching Annotations
  1. Nov 2021
    1. McNamara, L. A., Wiegand, R. E., Burke, R. M., Sharma, A. J., Sheppard, M., Adjemian, J., Ahmad, F. B., Anderson, R. N., Barbour, K. E., Binder, A. M., Dasgupta, S., Dee, D. L., Jones, E. S., Kriss, J. L., Lyons, B. C., McMorrow, M., Payne, D. C., Reses, H. E., Rodgers, L. E., … Schrag, S. J. (2021). Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: An ecological analysis of national surveillance data. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)02226-1

    1. The exact time is not known, but it is estimated to be a few weeks. 

      The half-life of the mRNA spike proteins is not exactly known, 16 Sept 2021.

    1. Benjamin Veness. (2021, November 2). Singapore’s 🇸🇬 Senior Minister of State for Health, Dr Janil Puthucheary, told Parliament on 1 November: “I hope my explanation has helped members understand why although we say we are living with COVID-19, we cannot just open up, and risk having the number of cases shoot up.” [Tweet]. @venessb. https://twitter.com/venessb/status/1455396047765733376

    1. ReconfigBehSci. (2021, November 2). interestingly the Singapore Health Minister also mentions “boosting through mild infections”—A concept that is currently generating much furore in the UK in the wake of the release of the JCVI minutes on child vaxx decisions 1/n [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1455445587910922240

  2. Oct 2021
    1. Sun, W., Liu, Y., Amanat, F., González-Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., Jangra, S., Rathnasinghe, R., Schotsaert, M., Martinez, J. L., Sano, K., Mena, I., Innis, B. L., Wirachwong, P., Thai, D. H., Oliveira, R. D. N., … Palese, P. (2021). A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 12(1), 6197. https://doi.org/10.1038/s41467-021-26499-y

    1. Gil Feldman. (2021, October 26). @EricTopol Updated data from Israel. The booster works, without any doubt! Red (empty battery): Un-vax Light green (half battery): 2nd dose without the booster Green (full battery): With the booster https://t.co/HbZBvDMQs6 [Tweet]. @feldman_gil. https://twitter.com/feldman_gil/status/1452845319251767299

    1. Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. The Lancet, 398(10309), 1407–1416. https://doi.org/10.1016/S0140-6736(21)02183-8

    1. Professor Lucy Easthope. (2021, October 20). WFH really is only for a very privileged few now. Not sure how that can stay a “thing” as an NPI. Too many harms being done by a fractured society where people are thriving by getting other people to bring them stuff/ make them things/ look after their family members for them [Tweet]. @LucyGoBag. https://twitter.com/LucyGoBag/status/1450842213613772802

    1. Hulme, W. J., Williamson, E. J., Green, A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., Tomlinson, L., Palmer, T., Horne, E., MacKenna, B., Morton, C. E., Mehrkar, A., Fisher, L., Bacon, S., Evans, D., … Goldacre, B. (2021). Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: A cohort study using OpenSAFELY [Preprint]. Epidemiology. https://doi.org/10.1101/2021.10.13.21264937

    1. Prof. Akiko Iwasaki. (2021, September 23). Thankfully, we have not seen any evidence of antibody-dependent enhancement of infection or disease by any COVID vaccines to date. Vaccine are not making infections worse, and are very effective in preventing disease. [Tweet]. @VirusesImmunity. https://twitter.com/VirusesImmunity/status/1441074260534075392

    1. Siddle, K. J., Krasilnikova, L. A., Moreno, G. K., Schaffner, S. F., Vostok, J., Fitzgerald, N. A., Lemieux, J. E., Barkas, N., Loreth, C., Specht, I., Tomkins-Tinch, C. H., Silbert, J., Schaeffer, B., Taylor, B. P., Loftness, B., Johnson, H., Schubert, P. L., Shephard, H. M., Doucette, M., … Sabeti, P. C. (2021). Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts (p. 2021.10.20.21265137). https://doi.org/10.1101/2021.10.20.21265137

    1. Following IM administration, the maximum concentration (Cmax) of the injection site muscle was 5,680 ng/mL, and the level declined with an estimated t1/2 of 18.8 hr

      Vaccine's halg-life was measured just below a day for mice muscles.

    2. The spleen and liver had a mean Cmax of 86.9 ng/mL

      Spleen & liver had x30 less mRNA concentration than Lymph nodes closest to the vaccine site, and x70 less the injected muscle.

    3. Proximal lymph nodes had the second highest concentration at 2,120 ng/mL (tmax of 8 hr with a relatively long t1/2 of 25.4 hr)

      Lymph-node mRNA half-life is a day.

    1. Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., Pandey, R., Brown, J., Zhou, J., Goonawardane, N., Mishra, S., Whittaker, C., Mellan, T., Marwal, R., Datta, M., … Gupta, R. K. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 1–6. https://doi.org/10.1038/s41586-021-03944-y

    1. John Roberts on Twitter: “154k booster 💉reported today in 🏴󠁧󠁢󠁥󠁮󠁧󠁿, bringing the total to 1.58m, out of 4.56m. So that’s another 3m eligible for a jab as soon as they can be scheduled in. 1/ https://t.co/tw1JmrOiUo” / Twitter. (n.d.). Retrieved October 15, 2021, from https://twitter.com/john_actuary/status/1445785517774176262

    1. Liverpool, M. L. P., Clare Wilson, Jessica Hamzelou, Sam Wong, Graham Lawton, Adam Vaughan, Conrad Quilty-Harper, Jason Arunn Murugesu and Layal. (n.d.). Covid-19 news: Study finds vaccines prevent over 84% of severe cases. New Scientist. Retrieved October 12, 2021, from https://www.newscientist.com/article/2237475-covid-19-news-study-finds-vaccines-prevent-over-84-of-severe-cases/

    1. Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., Rubin, C., Freedman, L., Kreiss, Y., & Regev-Yochay, G. (2021). Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2114583

    1. Palmer, T., Wallace, L., Pollock, K. G., Cuschieri, K., Robertson, C., Kavanagh, K., & Cruickshank, M. (2019). Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: Retrospective population study. BMJ, 365, l1161. https://doi.org/10.1136/bmj.l1161

    1. ReconfigBehSci. (2021, May 26). @Richard_Florida this is the Giesicke argument from Sweden- it makes sense only if you assume there will be no medical progress in the delay period. With vaccines and treatment improvements we know this to be empirically false. [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1397341753590489090

    1. Coronavirus Pandemic Data Explorer. (n.d.). Our World in Data. Retrieved March 3, 2021, from https://ourworldindata.org/coronavirus-data-explorer

      is:webpage lang:en COVID-19 graph case death Germany Sweden UK Afghanistan Africa Albania Algeria Andorra Angola Anguilla Antigua Barbuda Argentina Armenia Asia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Herzegovina Botswana Brazil Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Colombia Comoros Congo Costa Rica Cote d'ivoire Croatia Cuba Cyprus Czechia Democratic Republic of Congo Denmark Djobouti Dominica Dominician Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Europe Europian Union Faeroe Islands Falkland Islands Fiji Finland France Gabon Gambia Georgia Ghana Gibraltar Greece Greenland Grenada Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Mashall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Namibia Nepal Netherlands New Zealand Nicaragua Niger Nigeria North America North Macedonia Northern Cyprus Norway Oceania Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philipines Poland Portugal Qatar Romania Russia Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Vincent Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South America South Korea South Sudan Spain Sri Lanka Sudan Suriname Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Togo Trinidad Tobago Tunisia Turkey Turks and Caicos Islands Uganda Ukraine United Arab Emirates USA Uruguay Uzbekistan Vanuatu Vatican Venezuela Vietnam World Yemen Zambia Zimbabwe test vaccine chart map table data case fatality rate mortality

    Tags

    Annotators

    URL

    1. Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., Schultze-Florey, C., Ravens, I., Willenzon, S., Bubke, A., Ristenpart, J., Janssen, A., Ssebyatika, G., Bernhardt, G., Münch, J., … Behrens, G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 1–5. https://doi.org/10.1038/s41591-021-01449-9